Sol-Gel Technologies (SLGL) Non-Current Debt (2025)

Sol-Gel Technologies (SLGL) posted quarterly Non-Current Debt of $1.4 million for Q2 2025.

Sol-Gel Technologies (SLGL) Non-Current Debt (2025) Analysis & Trends

Sol-Gel Technologies (SLGL) has reported Non-Current Debt for 1 consecutive years, with $1.4 million the latest figure, recorded in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 882.16 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 8.96 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 546.77 Mn
10 Sol-Gel Technologies 240.26 Mn 230.12 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 1.36 Mn